Akademik Veri Yönetim Sistemi
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, cilt.48, sa.1, ss.23-32, 2024 (SCI-Expanded)
Objective. - The aim of this study is to evaluate correlation between Programmed cell death ligand 1 (PD -L1) mutation status with metabolic parameters derived from 18-F Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) in treatment naive non -small cell lung cancer (NSCLC). Material -methods. - PD -L1 mutation status was assessed by using the 22C3 DAKO (Group I; n:56), SP263 VENTANA (Group II; n:77) pharm kit in treatment naive NSCLC patients. Metabolic parameters, including volumetric ones of primary lesion (P), lymph node (LN) and distant metastases (M) obtained from FDG PET images. In order to standardize Standardized uptake values (SUVs) measured from images made on different PET/CT devices, SUVs were proportioned to liver(L) SUVs. Results. - In Group I, LN/L SUVmax/mean/peak and M/L SUVmean were significantly higher in cases with strongly positive PD -L1 mutation. In Group II, P/L SUVpeak and P TLG were significantly higher in cases with strongly positive PD -L1 mutation, while LN MTV mutation was higher in weakly positive cases. When all cases are evaluated together, P/L SUVmax/mean/peak, LN/L SUVmax/mean were significantly higher in strongly positive cases. On the other hand, M MTV was found to be higher in mutation -negative cases. Conclusion. - FDG PET can be used as complementary to molecular tests. It should be kept in mind that cases with primary lesions and lymph nodes with high SUVs may be PD -L1 mutant positive. In addition, MTV secondary to possible necrotic content in metastatic lymph nodes and distant organ lesions may be higher in PD -L1 mutation weak positive and negative cases. ⠂C 2023 Elsevier Masson SAS. All rights reserved.